Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Trabectedin demonstrated antineoplastic activity across cancer types by forming DNA adducts that induce DNA strand breaks, leading to cell cycle arrest and apoptosis, and by reducing tumor-associated macrophages and inhibiting cytokine and chemokine secretion in the tumor microenvironment.
• In specific cancer applications, trabectedin is approved for use in unresectable or metastatic liposome-associated leiomyosarcoma post-anthracycline treatment and is used in combination with pegylated liposomal doxorubicin for platinum-sensitive recurrent ovarian cancer in the European Union (EU).
• For metastatic synovial sarcoma (mSS), a pooled analysis indicated a median overall survival (mOS) of 10.4 months with trabectedin, comparable to pazopanib (mOS of 10.3 months), though pazopanib showed a higher overall response rate (ORR) of 18.9% compared to 12.3% for trabectedin.
• The incidence of cardiac toxicity in patients treated with trabectedin is approximately 3.4%, with an elevated risk of heart failure observed, particularly in patients with prior or concurrent anthracycline exposure; N-terminal pro B-type natriuretic peptide (NT-proBNP) monitoring may aid in the early detection of trabectedin-induced heart failure.
• Case reports highlight acute heart failure with preserved ejection fraction following trabectedin administration, underscoring the need for cardiac monitoring in high-risk populations.
• There is no population type or subgroup information available in the reviewed studies.